Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Infectious Diseases (London, England)|June 3, 2016
The mechanisms of delayed onset type adverse reactions to oseltamivirRokuro HamaNederlands Tijdschrift Voor Geneeskunde|September 5, 2019
[How transparent is the new Dutch guideline on cardiovascular risk management?]Dick BijlNederlands Tijdschrift Voor Geneeskunde|March 17, 2016
[New medicines at an acceptable cost?]Dick BijlThe International Journal of Risk & Safety in Medicine|May 5, 2020
Inadequate evaluation of potential side effects of sildenafil in preterm stopped Dutch trialDick Bijl, David HealyDrug, Healthcare and Patient Safety|April 22, 2015
Patient-reported outcomes after discontinuation of long-term topical corticosteroid treatment for atopic dermatitis: a targeted cross-sectional surveyNaoko Takahashi-Ando, Mark A Jones, Shigeki Fujisawa, et al.The International Journal of Risk & Safety in Medicine|December 14, 2011
Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenzaRokuro Hama, Mark Jones, Hiroki Okushima, et al.Pharmacology|January 22, 2018
A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017Harumi Okuyama, Tomohito Hamazaki, Rokuro Hama, et al.Expert Review of Clinical Pharmacology|February 7, 2015
Statins stimulate atherosclerosis and heart failure: pharmacological mechanismsHarumi Okuyama, Peter H Langsjoen, Tomohito Hamazaki, et al.The Cochrane Database of Systematic Reviews|January 20, 2012
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and childrenTom Jefferson, Mark A Jones, Peter Doshi, et al.BMJ Open|October 2, 2014
Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reportsTom Jefferson, Mark A Jones, Peter Doshi, et al.Pageof 2